Form 4 for XFOR X4 Pharmaceuticals, Inc
Accepted 2021-09-10 00:00:00 ET · period of report 2021-09-08 · accession 0001628280-21-018385 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-10 | 2021-09-08 | XFOR | DiBiase Mary | COO | A - Grant | $0.00 | +27.0K | 90.4K | +43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-08 | A | A | 27,000 | $0.00 | 90,444 | D | — | — | (F1) Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares will vest on each of September 8, 2022, September 8, 2023 and September 8, 2024, respectively, subject to the Reporting Person providing continuous service to the Issuer on such dates. |